MVZ DermaKiel GmbH
- Address
- Schönberger Str. 72-74, 24148 Kiel, Germany
Immune System Diseases
At MVZ DermaKiel GmbH in Kiel, the clinical research focus is on immune system diseases, especially birch pollen-induced allergic rhinitis and birch pollen-induced allergic rhinoconjunctivitis. The trials are designed to evaluate whether a new allergy treatment can reduce symptoms and lessen the need for medication during the birch pollen season.
- Study of allergic rhinitis linked to birch pollen exposure
- Research on allergic rhinoconjunctivitis and related seasonal allergy symptoms
- Assessment of a new allergy therapy aimed at improving symptom control
The site is contributing to research that may help improve treatment options for people affected by seasonal pollen allergies, with a clear emphasis on symptom relief and better disease management.
Allergic Rhinitis and Rhinoconjunctivitis Research
This dermatological practice is also involved in clinical trials centered on birch pollen allergy, focusing on how treatment affects both nasal and eye-related allergy symptoms. The main goal is to test the effectiveness of a candidate therapy in real-world seasonal conditions compared with placebo.
- Evaluation of treatment impact on seasonal allergy symptoms
- Investigation of symptom reduction and medication use during peak pollen exposure
- Support for better understanding of allergy treatment effectiveness
These studies reflect a practical effort to improve care for adolescents and adults living with recurring birch pollen-related allergic disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Inmunotek S.L.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MVZ DermaKiel GmbH
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous Mannan-Conjugated Betula Pendula Pollen Allergoid in Birch Pollen-Induced Allergic Rhinitis | CCDRD Cooperative Clinical Drug Research and Development AG, ClinCompetence Cologne GmbH, Inmunotek S.L. | Phase III | Not Recruiting | Feb 2024 | Jun 2024 |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Betula Pendula Pollen Allergoid, Mannan-Conjugated, Polymerised | 2 | Unknown | 2024-02-26 | 2024-10-28 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.